Medpace Holdings Inc vs Revolution Medicines Inc. Common Stock — how do they compare? Medpace Holdings Inc trades at $616.26 (market cap $16.82B), while Revolution Medicines Inc. Common Stock trades at $192.62 (market cap $40.32B). The key difference: Revolution Medicines Inc. Common Stock is far larger — about 2.4× Medpace Holdings Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Revolution Medicines Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Revolution Medicines Inc. Common Stock for 0 Days on average.
| MEDP | RVMD | |
|---|---|---|
Market Cap | $16.82B | $40.32B |
Volume | 223,093 | 4,855,734 |
Sector | Health | Health |
52-Week High | $630.19 | $221.15 |
52-Week Low | $393.42 | $47.50 |
Typical Hold Time | 14 Days | 0 Days |
Enterprise Value | $16.44B | $37.02B |
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $604.25, up 0.22% today, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue grew to $2.53 billion in 2025, with a net income margin of 17.67% and robust ROE of 162.15%. Analyst consensus is a $620.44 price target, though institutional sentiment is mixed with recent CEO share sales.
Outlook remains positive given earnings momentum and projected 2026 revenue growth to $2.8 billion. Key risks include high valuation multiples and insider selling. The stock offers upside to consensus target but requires monitoring of Q3 earnings and competitive pressures in medical services.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →Revolution Medicines develops precision medicines for cancer. Its programs focus on targeting RAS-driven cancers and related signaling pathways.
Read more on RVMD →